JP2006514967A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514967A5
JP2006514967A5 JP2004570040A JP2004570040A JP2006514967A5 JP 2006514967 A5 JP2006514967 A5 JP 2006514967A5 JP 2004570040 A JP2004570040 A JP 2004570040A JP 2004570040 A JP2004570040 A JP 2004570040A JP 2006514967 A5 JP2006514967 A5 JP 2006514967A5
Authority
JP
Japan
Prior art keywords
medicament
breast cancer
hydroxy tamoxifen
medium
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004570040A
Other languages
English (en)
Japanese (ja)
Other versions
JP5490346B2 (ja
JP2006514967A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/015029 external-priority patent/WO2004087123A1/en
Publication of JP2006514967A publication Critical patent/JP2006514967A/ja
Publication of JP2006514967A5 publication Critical patent/JP2006514967A5/ja
Application granted granted Critical
Publication of JP5490346B2 publication Critical patent/JP5490346B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004570040A 2003-04-01 2003-12-15 4−ヒドロキシタモキシフェンによる乳癌の予防および治療 Expired - Lifetime JP5490346B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
US60/458,963 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (3)

Publication Number Publication Date
JP2006514967A JP2006514967A (ja) 2006-05-18
JP2006514967A5 true JP2006514967A5 (https=) 2007-02-08
JP5490346B2 JP5490346B2 (ja) 2014-05-14

Family

ID=33131847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004570040A Expired - Lifetime JP5490346B2 (ja) 2003-04-01 2003-12-15 4−ヒドロキシタモキシフェンによる乳癌の予防および治療

Country Status (11)

Country Link
US (2) US7704516B2 (https=)
EP (3) EP1608353B1 (https=)
JP (1) JP5490346B2 (https=)
AU (1) AU2003294973B2 (https=)
CA (1) CA2519980C (https=)
ES (3) ES2483896T3 (https=)
IL (1) IL170807A (https=)
MX (1) MXPA05010597A (https=)
NO (1) NO333805B1 (https=)
NZ (1) NZ542499A (https=)
WO (1) WO2004087123A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054557A2 (en) * 2002-12-18 2004-07-01 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
JP4684655B2 (ja) * 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル 4−ヒドロキシタモキシフェンによる乳房密度低下
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) * 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
CN1946387B (zh) * 2004-03-22 2011-08-31 法国法杏大药厂 4-羟基三苯氧胺在制备治疗和预防良性乳房疾病的药物中的应用
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
WO2015175561A1 (en) 2014-05-12 2015-11-19 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
EP3230478B1 (en) 2014-12-12 2023-08-02 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
JP7131773B2 (ja) * 2016-04-29 2022-09-06 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム ホルモン受容体に関連する転写活性の標的尺度
IL304863B2 (en) 2017-09-11 2025-08-01 Atossa Therapeutics Inc Methods for making and using endoxifen
US20210299094A1 (en) * 2018-07-24 2021-09-30 Cornell University Methods of upregulating tiparp as anticancer strategies
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
WO2025019830A1 (en) * 2023-07-19 2025-01-23 Atossa Therapeutics, Inc. Anti-tumor compounds and methods of use thereof and synthesis thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (https=) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
ES2156361T5 (es) * 1996-03-29 2012-12-26 Keyvest Gmbh Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis"
EP1043986B1 (en) 1997-12-23 2003-04-16 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
CA2393762A1 (en) 1999-12-16 2001-06-21 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030175329A1 (en) 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
PT1317921E (pt) 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
JP4684655B2 (ja) * 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル 4−ヒドロキシタモキシフェンによる乳房密度低下
WO2004054557A2 (en) 2002-12-18 2004-07-01 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
CA2519980C (en) 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579857A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Similar Documents

Publication Publication Date Title
JP2006514967A5 (https=)
EA200600484A1 (ru) Доставка физиологических агентов in situ при помощи гелей, включающих анионные полисахариды
JP2008526757A5 (https=)
JP2005512995A5 (https=)
JP2006515598A5 (https=)
KR970706794A (ko) 치핵 치료용 조성물 및 이의 사용방법(Hemorrhoidal compositions and method of use)
JP2006505587A5 (https=)
JP2007511516A5 (https=)
JP2005525345A5 (https=)
JP2005520796A5 (https=)
CA2601289A1 (en) Once-a-day oxycodone formulations
JP2005515966A5 (https=)
ES2483896T3 (es) Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
EP0966966A3 (en) Nefazodone dosage form
JP2006514949A5 (https=)
JP2006514100A5 (https=)
Sivapathasundharam et al. Carcinoma cuniculatum of the alveolar mucosa: a rare variant of squamous cell carcinoma
JP2008513510A5 (https=)
JPH10147529A5 (https=)
Wankhedkar et al. Odontogenic myxoma in an 8-year-old girl: A case report with review of literature
JP2021531237A (ja) U字型口腔用薄膜
JP2007504268A5 (https=)
CA2504873A1 (en) Percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one
JP2002537246A5 (https=)
MXPA06000363A (es) Forma de dosificacion oral de mesilato de saquinavir.